Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer MCMs were applied to patient-level ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback